Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZR75B | HR+ | Luminal | 5-FU | TYMS | TYMS | 19200 | uM | 9972.017 | 0.1936 | -0.5105 | 1.1666 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12509.165 | 0.9871 | 0.9828 | 1.5022 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12509.165 | 0.9788 | 0.9717 | 1.5022 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12509.165 | 0.9185 | 0.8899 | 1.5022 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12509.165 | 0.5575 | 0.3556 | 1.5022 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12509.165 | 0.3373 | -0.0298 | 1.5022 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12509.165 | 0.3318 | -0.0404 | 1.5022 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12509.165 | 0.3136 | -0.0757 | 1.5022 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12509.165 | 0.0484 | -0.7335 | 1.5022 | |
| 184A1 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12509.165 | 0.0097 | -0.9088 | 1.5022 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12566.165 | 1.0934 | 1.1063 | 1.7248 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12566.165 | 0.9615 | 0.9550 | 1.7248 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12566.165 | 0.9100 | 0.8936 | 1.7248 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12566.165 | 0.7623 | 0.7088 | 1.7248 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12566.165 | 0.4635 | 0.2805 | 1.7248 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12566.165 | 0.4213 | 0.2116 | 1.7248 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12566.165 | 0.4081 | 0.1896 | 1.7248 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12566.165 | 0.0244 | -0.7679 | 1.7248 | |
| 184B5 | NM | Basal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12566.165 | 0.0100 | -0.8618 | 1.7248 | |
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12224.165 | 0.9676 | 0.9334 | 0.9714 | |
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12224.165 | 0.9430 | 0.8827 | 0.9714 | |
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12224.165 | 0.9166 | 0.8284 | 0.9714 | |
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12224.165 | 0.9079 | 0.8106 | 0.9714 | |
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12224.165 | 0.7689 | 0.5260 | 0.9714 | |
| 600MPE | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12224.165 | 0.8090 | 0.6079 | 0.9714 |